IL4 and neoplasm: By combining a first-generation anti-PSCA CAR with two hybrid cytokine receptors to convert immunosuppressive transforming growth factor beta (TGFβ) and interleukin 4 (IL4) cytokine signaling into co-stimulatory signaling,230 maximal CAR-T cell activity was restricted to the tumor site.